RT Journal Article
SR Electronic
T1 Integrative Systems Immunology Analysis Reveals Elevated Anti-AGTR1 Levels with Accumulating COVID-19 Symptoms
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.04.05.24305287
DO 10.1101/2024.04.05.24305287
A1 Fonseca, Dennyson Leandro M
A1 Jäpel, Maj
A1 Filgueiras, Igor Salerno
A1 Baiochi, Gabriela Crispim
A1 Ostrinski, Yuri
A1 Halpert, Gilad
A1 Lavi, Yael Bublil
A1 Vojdani, Elroy
A1 Santos e Silva, Juan Carlo
A1 Usuda, Júlia Nakanishi
A1 Freire, Paula P.
A1 Nóbile, Adriel Leal
A1 Adri, Anny Silva
A1 Marçal, Pedro Barcelos
A1 Corrêa, Yohan Lucas Gonçalves
A1 Nery do Vale, Fernando Yuri
A1 Lopes, Letícia Oliveira
A1 Schmidt, Solveig Lea
A1 Wang, Xiaoqing
A1 Vahldieck, Carl
A1 Fels, Benedikt
A1 Schimke, Lena F.
A1 Hirata, Mario Hiroyuki
A1 Miranda, Gustavo Cabral-
A1 AKhan, Taj Ali
A1 Catar, Rusan
A1 Moll, Guido
A1 Silva-Sousa, Thayna
A1 Yu, Yen-Rei A
A1 Dalmolin, Rodrigo JS
A1 Amital, Howard
A1 Vojdani, Aristo
A1 Nakaya, Helder
A1 Ochs, Hans D.
A1 Silverberg, Jonathan I.
A1 Zimmerman, Jason
A1 Zyskind, Israel
A1 Rosenberg, Avi Z
A1 Schulze-Forster, Kai
A1 Heidecke, Harald
A1 Hackel, Alexander
A1 Kusche-Vihrog, Kristina
A1 Shoenfeld, Yehuda
A1 Riemekasten, Gabriela
A1 Akbarzadeh, Reza
A1 Marques, Alexandre H.C
A1 Cabral-Marques, Otavio
YR 2024
UL http://medrxiv.org/content/early/2024/04/09/2024.04.05.24305287.abstract
AB The coronavirus disease 2019 (COVID-19) displays a broad spectrum of symptoms, with the underlying reasons for this variability still not fully elucidated. Our study investigates the potential association between specific autoantibodies (AABs), notably those that targeting G protein-coupled receptors (GPCRs) and renin-angiotensin system (RAS) related molecules, and the diverse clinical manifestations of COVID-19, commonly observed in patients with autoimmune conditions, including rheumatic diseases, such as systemic sclerosis. In a cross-sectional analysis, we explored the relationship between AAB levels and the presence of key COVID-19 symptoms. Hierarchical clustering analysis revealed a robust correlation between certain AABs and symptoms such as fever, muscle ache, anosmia, and dysgeusia, which emerged as significant predictors of disease severity. Specifically, AABs against CHRM5 and CXCR3 were strongly linked to fever, while AABs against CHRM5 and BDKRB1 correlated with muscle ache. Anosmia was predominantly associated with AABs against F2R and AGTR1, while dysgeusia was linked to AABs against BDKRB1 and AGTR1. Furthermore, we observed a rise in AAB levels with the accumulation of these symptoms, with the highest levels detected in patients presenting all four predictors. Multinomial regression analysis identified AABs targeting AGTR1 as a key predictor for one or more of these core symptoms. Additionally, our study indicated that anti-AGTR1 antibodies triggered a concentration-dependent degradation of eGC, which could be mitigated by the AGTR1 antagonist Losartan. This suggests a potential mechanistic connection between eGC degradation, the observed COVID-19 symptoms, and rheumatic diseases. In conclusion, our research underscores a substantial correlation between AABs, particularly those against GPCRs and RAS-related molecules, and the severity of COVID-19 symptoms. These findings open avenues for potential therapeutic interventions in the management of COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe would like to recognize the contributions of Lev Rochel Bikur Cholim of Lakewood, Sao Paulo Research Foundation, National Council for Scientific and Technological Development, Coordination of Superior Level Staff Improvement, and German Research Foundation,Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study received approval from the IntegReview institutional review board (Coronavirus Antibody Prevalence Study, CAPS-613) and adhered to the reporting guidelines outlined by Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript